<p>Takeda’s $5.2 billion takeover of Ariad Pharmaceuticals is turning into a major payday for a weighty but unheralded investor in the drug sector. Sarissa Capital, run by Carl Icahn protégé Alex Denner, stands to make $260 million on Monday’s deal.</p>
<p>Ariad, which sells a $199,000 a year treatment for blood clots called Iclusig, is being taken over by Takeda for $24 a share, or a 75% premium to its Friday closing price. But that eye-popping takeover premium only hints at Sarissa Capital’s Ariad payday.</p>